8-K: Adverum Biotechnologies Announces Positive Clinical Data, $127.5 Million Financing, and Reverse Stock Split

Adverum Biotechnologies reported positive preliminary data from its LUNA Phase 2 trial for Ixo-vec in wet AMD, completed a $127.5 million private placement, and announced a 1-for-10 reverse stock split.

Summary

• Adverum Biotechnologies announced its fourth quarter and full year 2023 financial results, along with pipeline and corporate updates.
• The company presented preliminary data from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the Macula Society meeting, showing potentially best-in-class clinical activity.
• Patients in the LUNA trial experienced significant reductions in anti-VEGF injections, with 90% and 94% reductions at the 2E11 and 6E10 doses, respectively.
• 85% and 68% of patients at the 2E11 and 6E10 doses, respectively, required no supplemental injections through 26 weeks.
• The company completed a $127.5 million private placement financing, extending its cash runway into late 2025.
• A 1-for-10 reverse stock split will be effective on March 21, 2024.
• Cash, cash equivalents, and short-term investments were $96.5 million as of December 31, 2023, and pro forma cash was $223.8 million after the private placement.
• Research and development expenses were $15.3 million for the quarter ended December 31, 2023, compared to $22.2 million for the same period in 2022.
• Net loss for the quarter was $23.7 million, or $0.23 per share, compared to a net loss of $32.7 million, or $0.33 per share, for the same period in 2022.

Sentiment

Score: 8

Explanation: The document is very positive due to the strong clinical data, successful financing, and clear path forward. The reverse stock split is a minor negative, but the overall tone is optimistic.

Positives

• The LUNA trial data suggests Ixo-vec could be a best-in-class treatment for wet AMD.
• The significant reduction in anti-VEGF injections and the high percentage of patients needing no supplemental injections are very encouraging.
• The $127.5 million private placement provides substantial funding and extends the cash runway into late 2025.
• The appointment of a new Chief Scientific Officer with significant experience in gene therapy is a positive development.
• The company has maintained or improved mean BCVA and mean CST at both dose levels in the LUNA trial.
• Ixo-vec was generally well tolerated in the LUNA trial, with no Ixo-vec related serious adverse events reported.

Negatives

• The company reported a net loss of $23.7 million for the quarter ended December 31, 2023.
• Cash reserves decreased from $185.6 million at the end of 2022 to $96.5 million by the end of 2023, before the private placement.
• The reverse stock split, while necessary, may be viewed negatively by some investors.

Risks

• The company is still in the clinical trial phase, and there is no guarantee that Ixo-vec will be approved by regulatory agencies.
• The company is dependent on the success of its Ixo-vec program.
• Market conditions could impact the company's ability to raise additional capital in the future.
• There are risks associated with the development of gene therapies, including potential adverse events.
• The company faces competition from other companies developing treatments for wet AMD.

Future Outlook

The company expects its cash to fund operations into late 2025 and plans to initiate a Phase 3 trial of Ixo-vec in the first half of 2025. They also anticipate presenting the 26-week interim analysis of the LUNA Phase 2 program in mid-2024.

Management Comments

• We have made tremendous progress during 2023 and in 2024 to date in our development of Ixo-vec as a durable potential gene therapy treatment for the millions of patients suffering from wet AMD, stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
• We were pleased to present at Macula Society preliminary data from our ongoing LUNA Phase 2 trial of Ixo-vec, which demonstrated potentially best-in-class clinical activity at both the 2E11 and 6E10 doses of Ixo-vec, with the data trending similar to, or better than, the data in our first-in-human OPTIC trial.
• In the lead-up to the data presentation at Macula Society, Adverum completed a $127.5 million private placement financing with new and existing investors that we expect to meaningfully extend our cash runway into late 2025, well beyond the anticipated presentation of topline 52-week data from our ongoing LUNA Phase 2 trial.

Industry Context

The announcement is significant in the context of the broader gene therapy field, particularly for ocular diseases. The positive data from the LUNA trial positions Adverum as a potential leader in the wet AMD treatment space, which currently relies on frequent injections. The successful private placement also highlights investor interest in the gene therapy sector.

Comparison to Industry Standards

• The reported 90% and 94% reduction in annualized anti-VEGF injections in the LUNA trial at the 2E11 and 6E10 doses, respectively, are very competitive compared to existing treatments for wet AMD, such as aflibercept (Eylea) and ranibizumab (Lucentis), which require frequent injections.
• The 85% and 68% of patients receiving no supplemental injections through 26 weeks at the 2E11 and 6E10 doses, respectively, are also very promising compared to the current standard of care.
• Other companies in the gene therapy space for ocular diseases include companies like REGENXBIO and MeiraGTx, but Adverum's approach of a one-time IVT injection is a differentiator.
• The long-term data from the OPTIC trial, showing sustained reduction in anti-VEGF treatment burden through 3 years, is also a positive indicator of the potential durability of Ixo-vec.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split and the potential for future share price appreciation based on clinical trial results.
• Employees may benefit from the company's extended cash runway and continued development of Ixo-vec.
• Patients with wet AMD could benefit from a new treatment option that reduces the need for frequent injections.
• Investors are likely to be encouraged by the positive clinical data and the successful private placement.

Next Steps

• The company will continue formal and informal regulatory interactions with the FDA and EMA.
• The 26-week interim analysis of the LUNA Phase 2 program is expected in mid-2024.
• The company plans to initiate a Phase 3 trial of Ixo-vec in the first half of 2025.

Key Dates

Keywords

Ixo-vec, wet AMD, gene therapy, clinical trial, private placement, reverse stock split, anti-VEGF, LUNA trial, ophthalmology, biotechnology